The proposed notification requirement is straightforward, but its legal and commercial consequences are not.
|Articles|September 26, 2022
White Paper: YES-10® for Mood Support
Author(s)Famenity
YES-10® is a proprietary blend of natural botanical ingredients. A double-blind, randomized, placebo-controlled human clinical trial found that Famenity’s YES-10® demonstrated significant reduction in serum cortisol levels and exerted significant improvements in the Beck Depression Inventory, Beck Anxiety Inventory, Psychological Well-being Index, and the Mental Fitness Scale tests scores. YES-10® is a natural ingredient that may help with mood support, stress reduction, and a general sense of well-being.
Related to this article
The company plans to unveil a clinically studied ingredient on opening day and host a longevity session alongside its cognitive, mobility, and metabolic health portfolio.
The Watsonville, California, supplier will sample formats built on its lion’s mane and multi-species mushroom ingredients, following a recent facility expansion.
With Peru's anchovy fishery opening its 2026 season with its lowest quota in a decade, Matts Johansen argues that aquaculture's growing appetite for omega-3s, not just El Niño, is what should actually be keeping supplement brands up at night.
The palm phytonutrient supplier will show STGaia, TocoGaia, and PetGaia at the event and preview a planned research grant program.
Formulators are moving toward botanicals like ashwagandha, bacopa, saffron, and PEA that target the stress, cortisol, and nervous-system pathways behind restless nights.
Emerging plant protein sources are redefining how protein products are formulated.
The four-formula line is Olly’s second retailer-exclusive launch this year, following the launch of a probiotic range in April.
Trending on Nutritional Outlook - Supplement, Food & Beverage Manufacturing Trends
1
Givaudan to Reveal New Metabolic Health Botanical at SupplySide Global 2026
2
Beyond the Symptom: How Botanicals Are Redefining the Sleep Health Category
3
Omega-3 Supply, Not Price, Is the Real Threat
4
FDA’s Proposed GRAS Rule, and What Industry Should Do Now
5